PSMC6抗体

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Raji cells using CD3G mouse mAb (green) and negative control (red).    

  
  

The PSMC6 antibody targets the Proteasome 26S Subunit, ATPase 6 (PSMC6), a critical component of the 19S regulatory particle within the 26S proteasome complex. The 26S proteasome is responsible for ATP-dependent degradation of ubiquitinated proteins, a central process in maintaining cellular protein homeostasis. PSMC6. as one of six AAA-ATPase subunits (PSMC1-6) in the 19S regulatory particle, plays a key role in recognizing ubiquitinated substrates, unfolding them, and translocating them into the proteasome's catalytic core for proteolysis. Dysregulation of proteasome function, including PSMC6 activity, has been implicated in cancer, neurodegenerative diseases (e.g., Alzheimer's, Parkinson's), and immune disorders.

PSMC6 antibodies are widely used as research tools to study proteasome composition, protein turnover mechanisms, and disease-associated alterations in ubiquitin-proteasome system (UPS) activity. Common applications include Western blotting, immunoprecipitation, and immunohistochemistry. These antibodies are typically developed in hosts such as rabbits or mice, with both monoclonal and polyclonal variants available. Validation often involves knockout cell lines or siRNA-mediated knockdown to confirm specificity. Researchers also utilize PSMC6 antibodies to investigate the effects of proteasome inhibitors (e.g., bortezomib) in cancer therapy and to explore UPS-related stress responses in cellular models.